{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:49:27Z","timestamp":1792532967480,"version":"4.5.0"},"reference-count":37,"publisher":"Bioscientifica","issue":"11","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,28]]},"abstract":"<jats:p>\n                    Immune checkpoint inhibitors (ICIs) can trigger immune-related adverse events (irAEs). The appearance pattern of irAEs, who is prone to them, and their mechanisms are still uncertain. In this study, we aimed to monitor patients initiated on ICIs for endocrinological aspects and to investigate the potential predictive markers in the development of endocrine-irAEs. The study prospectively included 43 patients with metastatic disease scheduled for anti-PD-1\/L1 therapy. Endocrinological follow-up was conducted at specified intervals as well as in response to any additional reported complaints. Serum concentrations of CXCL10, IL-1beta, and IL-17A were measured prior to ICI and during the endocrine-irAEs. A total of 39.5% of the patients experienced endocrine-irAEs, with a median onset time of 3 months. Among patients, 34.9% developed thyroid-related adverse events, and 4.6% experienced hypophysitis. Thyroid autoantibodies were associated with a higher incidence of thyroid-related irAEs (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.004). In the irAE group, median pre-ICI CXCL10 and baseline thyroid stimulating hormone (TSH) levels were significantly higher, baseline total testosterone level in men was lower than in the non-irAE group (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05), whereas IL-1beta and IL-17A levels did not differ (\n                    <jats:italic>P<\/jats:italic>\n                    &gt; 0.05). Serum CXCL10, IL-1beta, and IL-17A concentrations did not differ significantly pre-ICI and during adverse events (\n                    <jats:italic>P<\/jats:italic>\n                    &gt; 0.05). Pre-ICI CXCL10 concentration was correlated positively with anti-TPO levels in patients with at least one thyroid autoantibody positivity (\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u20090.706,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.01) and negatively with baseline total testosterone level of men (\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u20090.509,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.002). Our results suggest that higher pre-ICI serum CXCL10 and TSH levels might have a predictive role in the development of endocrinopathies. Besides, baseline thyroid antibody measurements could be beneficial in predicting thyroid dysfunction.\n                  <\/jats:p>","DOI":"10.1530\/erc-24-0101","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T07:18:32Z","timestamp":1724829512000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":12,"title":["Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center"],"prefix":"10.1530","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0042-6928","authenticated-orcid":true,"given":"Tugba","family":"Barlas","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Gazi University, Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Sutcuoglu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gazi University, Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhun","family":"Akdogan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gazi University, Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusun","family":"Balos Toruner","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Gazi University, Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mujde","family":"Akturk","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Gazi University, Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuriye","family":"Ozdemir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gazi University, Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan","family":"Yazici","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gazi University, Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alev","family":"Eroglu Altinova","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Gazi University, Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Experimental and Clinical Endocrinology and Diabetes","first-page":"267","article-title":"Hypothyroidism in cancer patients on immune checkpoint inhibitors with anti-PD1 agents: insights on underlying mechanisms","volume":"125","author":"Alhusseini","year":"2017","unstructured":"Alhusseini M & Samantray J2017Hypothyroidism in cancer patients on immune checkpoint inhibitors with anti-PD1 agents: insights on underlying mechanisms. Experimental and Clinical Endocrinology and Diabetes125267\u2013269. (https:\/\/doi.org\/10.1055\/s-0042-119528)"},{"key":"bib2","series-title":"Experimental and Therapeutic Medicine","first-page":"10","article-title":"Diabetes insipidus: a rare endocrine complication of immune check point inhibitors: a case report and literature review","volume":"25","author":"Angelousi","year":"2023","unstructured":"Angelousi APapalexis PKarampela AMarra MMisthos DZiogas D & Gogas H2023Diabetes insipidus: a rare endocrine complication of immune check point inhibitors: a case report and literature review. Experimental and Therapeutic Medicine2510. (https:\/\/doi.org\/10.3892\/etm.2022.11709)"},{"key":"bib3","series-title":"European Journal of Endocrinology","first-page":"1","article-title":"Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase","volume":"182","author":"Bai","year":"2020","unstructured":"Bai XChen XWu XHuang YZhuang Y & Lin X2020Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. European Journal of Endocrinology1821\u20139. (https:\/\/doi.org\/10.1530\/EJE-19-0535)"},{"key":"bib4","series-title":"Frontiers in Immunology","first-page":"974087","article-title":"The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy","volume":"13","author":"Botticelli","year":"2022","unstructured":"Botticelli APomati GCirillo AScagnoli SPisegna SChiavassa ARossi ESchinzari GTortora GDi Pietro FR, et al.2022The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy. Frontiers in Immunology13974087. (https:\/\/doi.org\/10.3389\/fimmu.2022.974087)"},{"key":"bib5","series-title":"Gene","first-page":"8","article-title":"Interluekin-17A (IL17A)","volume":"614","author":"Chen","year":"2017","unstructured":"Chen K & Kolls JK2017Interluekin-17A (IL17A). Gene6148\u201314. (https:\/\/doi.org\/10.1016\/j.gene.2017.01.016)"},{"key":"bib6","series-title":"Frontiers in Oncology","first-page":"1037884","article-title":"Review of biomarkers for response to immunotherapy in HNSCC microenvironment","volume":"13","author":"Chen","year":"2023","unstructured":"Chen SYang YHe SLian MWang R & Fang J2023Review of biomarkers for response to immunotherapy in HNSCC microenvironment. Frontiers in Oncology131037884. (https:\/\/doi.org\/10.3389\/fonc.2023.1037884)"},{"key":"bib7","series-title":"Immunity","first-page":"1498","article-title":"Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy","volume":"50","author":"Chow","year":"2019","unstructured":"Chow MTOzga AJServis RLFrederick DTLo JAFisher DEFreeman GJBoland GM & Luster AD2019Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity501498\u20131512.e5. (https:\/\/doi.org\/10.1016\/j.immuni.2019.04.010)"},{"key":"bib8","series-title":"Endocrine Journal","first-page":"345","article-title":"Correlation between, clinical, biochemical, color Doppler ultrasound thyroid parameters, and CXCL-10 in autoimmune thyroid diseases","volume":"55","author":"Corona","year":"2008","unstructured":"Corona GBiagini CRotondi MBonamano ACremonini NPetrone LConforti BForti G & Serio M2008Correlation between, clinical, biochemical, color Doppler ultrasound thyroid parameters, and CXCL-10 in autoimmune thyroid diseases. Endocrine Journal55345\u2013350. (https:\/\/doi.org\/10.1507\/endocrj.k07e-052)"},{"key":"bib9","series-title":"Hormone and Metabolic Research","first-page":"145","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"De Filette","year":"2019","unstructured":"De Filette JAndreescu CECools FBravenboer B & Velkeniers B2019A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Hormone and Metabolic Research51145\u2013156. (https:\/\/doi.org\/10.1055\/a-0843-3366)"},{"key":"bib10","series-title":"Nature Reviews. Rheumatology","first-page":"612","article-title":"The IL-1 family of cytokines and receptors in rheumatic diseases","volume":"15","author":"Dinarello","year":"2019","unstructured":"Dinarello CA2019The IL-1 family of cytokines and receptors in rheumatic diseases. Nature Reviews. Rheumatology15612\u2013632. (https:\/\/doi.org\/10.1038\/s41584-019-0277-8)"},{"key":"bib11","series-title":"Journal of Cancer Research and Clinical Oncology","first-page":"7925","article-title":"Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features","volume":"149","author":"Esteves-Ferreira","year":"2023","unstructured":"Esteves-Ferreira S & Rosinha P2023Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features. Journal of Cancer Research and Clinical Oncology1497925\u20137932. (https:\/\/doi.org\/10.1007\/s00432-023-04659-5)"},{"key":"bib12","series-title":"Autoimmunity Reviews","first-page":"102785","article-title":"The revisited role of interleukin-1 alpha and beta in autoimmune and inflammatory disorders and in comorbidities","volume":"20","author":"Galozzi","year":"2021","unstructured":"Galozzi PBindoli SDoria A & Sfriso P2021The revisited role of interleukin-1 alpha and beta in autoimmune and inflammatory disorders and in comorbidities. Autoimmunity Reviews20102785. (https:\/\/doi.org\/10.1016\/j.autrev.2021.102785)"},{"key":"bib13","series-title":"JAMA Network Open","first-page":"e192535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","unstructured":"Haslam A & Prasad V2019Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Network Open2e192535. (https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.2535)"},{"key":"bib14","series-title":"Prostate","first-page":"336","article-title":"Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy","volume":"80","author":"Hawley","year":"2020","unstructured":"Hawley JEPan SFigg WDLopez-Bujanda ZAStrope JDAggen DHDallos MCLim EAStein MNHu J, et al.2020Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy. Prostate80336\u2013344. (https:\/\/doi.org\/10.1002\/pros.23948)"},{"key":"bib16","series-title":"Clinical Cancer Research","first-page":"487","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","unstructured":"House IGSavas PLai JChen AXOliver AJTeo ZLTodd KLHenderson MAGiuffrida LPetley EV, et al.2020Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clinical Cancer Research26487\u2013504. (https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1868)"},{"key":"bib17","series-title":"International Journal of Molecular Sciences","first-page":"2642","article-title":"CXC chemokine signaling in progression of epithelial ovarian cancer: theranostic perspectives","volume":"23","author":"Huang","year":"2022","unstructured":"Huang XHao JTan YQZhu TPandey V & Lobie PE2022CXC chemokine signaling in progression of epithelial ovarian cancer: theranostic perspectives. International Journal of Molecular Sciences232642. (https:\/\/doi.org\/10.3390\/ijms23052642)"},{"key":"bib18","series-title":"European Journal of Endocrinology","first-page":"G1","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","unstructured":"Husebye ESCastinetti FCriseno SCurigliano GDecallonne BFleseriu MHigham CELupi IPaschou SAToth M, et al.2022Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. European Journal of Endocrinology187G1\u2013G21. (https:\/\/doi.org\/10.1530\/EJE-22-0689)"},{"key":"bib19","series-title":"Annales d'Endocrinologie","first-page":"555","article-title":"Expert opinion on thyroid complications in immunotherapy","volume":"79","author":"Illouz","year":"2018","unstructured":"Illouz FDrui DCaron P & Do Cao C2018Expert opinion on thyroid complications in immunotherapy. Annales d'Endocrinologie79555\u2013561. (https:\/\/doi.org\/10.1016\/j.ando.2018.07.007)"},{"key":"bib20","series-title":"British Journal of Cancer","first-page":"63","article-title":"Immune dysregulation in cancer patients developing immune-related adverse events","volume":"120","author":"Khan","year":"2019","unstructured":"Khan SKhan SALuo XFattah FJSaltarski JGloria-Mccutchen YLu RXie YLi QWakeland E, et al.2019Immune dysregulation in cancer patients developing immune-related adverse events. British Journal of Cancer12063\u201368. (https:\/\/doi.org\/10.1038\/s41416-018-0155-1)"},{"key":"bib21","series-title":"Oncoimmunology","first-page":"2118210","article-title":"CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy","volume":"11","author":"Li","year":"2022","unstructured":"Li XLu MYuan MYe JZhang WXu LWu XHui BYang YWei B, et al.2022CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy. Oncoimmunology112118210. (https:\/\/doi.org\/10.1080\/2162402X.2022.2118210)"},{"key":"bib22","series-title":"Cytokine","first-page":"155363","article-title":"Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer","volume":"138","author":"Lim","year":"2021","unstructured":"Lim JU & Yoon HK2021Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer. Cytokine138155363. (https:\/\/doi.org\/10.1016\/j.cyto.2020.155363)"},{"key":"bib23","series-title":"Clinical Cancer Research","first-page":"5250","article-title":"Intratumoral adaptive immunosuppression and type 17 immunity in mismatch repair proficient colorectal tumors","volume":"25","author":"Llosa","year":"2019","unstructured":"Llosa NJLuber BTam AJSmith KNSiegel NAwan AHFan HOke TZhang JDomingue J, et al.2019Intratumoral adaptive immunosuppression and type 17 immunity in mismatch repair proficient colorectal tumors. Clinical Cancer Research255250\u20135259. (https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0114)"},{"key":"bib24","series-title":"Endocrine, Metabolic & Immune Disorders Drug Targets","article-title":"Endocrine adverse events related to immune checkpoint inhibitor treatment: relationship between antibodies and severity of thyroid dysfunction","author":"Migu\u00e9lez Gonz\u00e1lez","year":"2024","unstructured":"Migu\u00e9lez Gonz\u00e1lez MGald\u00f3n Sanz-Pastor A\u00c1\u00f1ez G\u00f3mez RBrox Torrecilla NMu\u00f1oz Moreno DGonz\u00e1lez Fern\u00e1ndez LMaricel Rivas AL\u00f3pez Guerra A\u00c1lvarez RArranz J\u00c1, et al.2024Endocrine adverse events related to immune checkpoint inhibitor treatment: relationship between antibodies and severity of thyroid dysfunction. Endocrine, Metabolic & Immune Disorders Drug Targets. (https:\/\/doi.org\/10.2174\/0118715303280679240206100137)"},{"key":"bib25","series-title":"International Journal of Molecular Sciences","first-page":"2088","article-title":"Chemokines from a structural perspective","volume":"18","author":"Miller","year":"2017","unstructured":"Miller MC & Mayo KH2017Chemokines from a structural perspective. International Journal of Molecular Sciences182088. (https:\/\/doi.org\/10.3390\/ijms18102088)"},{"key":"bib26","series-title":"Best Practice and Research. Clinical Endocrinology and Metabolism","first-page":"101668","article-title":"Immune checkpoint inhibitor-related hypophysitis","volume":"36","author":"Mizukoshi","year":"2022","unstructured":"Mizukoshi TFukuoka H & Takahashi Y2022Immune checkpoint inhibitor-related hypophysitis. Best Practice and Research. Clinical Endocrinology and Metabolism36101668. (https:\/\/doi.org\/10.1016\/j.beem.2022.101668)"},{"key":"bib27","series-title":"Best Practice and Research. Clinical Endocrinology and Metabolism","first-page":"101411","article-title":"Check point inhibitors and autoimmunity: why endocrinopathies and who is prone to?","volume":"34","author":"Percik","year":"2020","unstructured":"Percik R & Shoenfeld Y2020Check point inhibitors and autoimmunity: why endocrinopathies and who is prone to?Best Practice and Research. Clinical Endocrinology and Metabolism34101411. (https:\/\/doi.org\/10.1016\/j.beem.2020.101411)"},{"key":"bib28","series-title":"Endocrine Practice","first-page":"824","article-title":"Baseline TSH level is associated with risk of anti\u2013PD-1\u2013induced thyroid dysfunction","volume":"25","author":"Pollack","year":"2019","unstructured":"Pollack RMKagan MLotem M & Dresner-Pollak R2019Baseline TSH level is associated with risk of anti\u2013PD-1\u2013induced thyroid dysfunction. Endocrine Practice25824\u2013829. (https:\/\/doi.org\/10.4158\/EP-2018-0472)"},{"key":"bib29","series-title":"Seminars in Cancer Biology","first-page":"1105","article-title":"Multifaceted role of chemokines in solid tumors: from biology to therapy","volume":"86","author":"Raza","year":"2022","unstructured":"Raza SRajak STewari AGupta PChattopadhyay NSinha RA & Chakravarti B2022Multifaceted role of chemokines in solid tumors: from biology to therapy. Seminars in Cancer Biology861105\u20131121. (https:\/\/doi.org\/10.1016\/j.semcancer.2021.12.011)"},{"key":"bib30","series-title":"Journal of Immunology","first-page":"2522","article-title":"Testosterone suppresses hepatic inflammation by the downregulation of IL-17, CXCL-9, and CXCL-10 in a mouse model of experimental acute cholangitis","volume":"194","author":"Schwinge","year":"2015","unstructured":"Schwinge DCarambia AQuaas AKrech TWegscheid CTiegs GPrinz ILohse AWHerkel J & Schramm C2015Testosterone suppresses hepatic inflammation by the downregulation of IL-17, CXCL-9, and CXCL-10 in a mouse model of experimental acute cholangitis. Journal of Immunology1942522\u20132530. (https:\/\/doi.org\/10.4049\/jimmunol.1400076)"},{"key":"bib31","series-title":"Immunotherapy","first-page":"261","article-title":"Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis","volume":"9","author":"Shang","year":"2017","unstructured":"Shang YHZhang YLi JHLi P & Zhang X2017Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis. Immunotherapy9261\u2013272. (https:\/\/doi.org\/10.2217\/imt-2016-0147)"},{"key":"bib32","series-title":"Theranostics","first-page":"7175","article-title":"CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors","volume":"11","author":"Shi","year":"2021","unstructured":"Shi ZShen JQiu JZhao QHua K & Wang H2021CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors. Theranostics117175\u20137187. (https:\/\/doi.org\/10.7150\/thno.59056)"},{"key":"bib33","series-title":"Endocrine Connections","first-page":"R207","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review","volume":"9","author":"Stelmachowska-Bana\u015b","year":"2020","unstructured":"Stelmachowska-Bana\u015b M & Czajka-Oraniec I2020Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocrine Connections9R207\u2013R228. (https:\/\/doi.org\/10.1530\/EC-20-0342)"},{"key":"bib34","series-title":"Cancer Treatment Reviews","first-page":"40","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation\u2013a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","unstructured":"Tokunaga RZhang WNaseem MPuccini ABerger MDSoni SMcskane MBaba H & Lenz H-J2018CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation\u2013a target for novel cancer therapy. Cancer Treatment Reviews6340\u201347. (https:\/\/doi.org\/10.1016\/j.ctrv.2017.11.007)"},{"key":"bib35","series-title":"Cancer Discovery","first-page":"1069","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","unstructured":"Wei SCDuffy CR & Allison JP2018Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discovery81069\u20131086. (https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0367)"},{"key":"bib36","series-title":"Nature Reviews. Endocrinology","first-page":"389","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","unstructured":"Wright JJPowers AC & Johnson DB2021Endocrine toxicities of immune checkpoint inhibitors. Nature Reviews. Endocrinology17389\u2013399. (https:\/\/doi.org\/10.1038\/s41574-021-00484-3)"},{"key":"bib37","series-title":"Frontiers in Endocrinology","first-page":"649863","article-title":"Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management","volume":"12","author":"Zhan","year":"2021","unstructured":"Zhan LFeng H-FLiu H-QGuo L-TChen CYao X-L & Sun S-R2021Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management. Frontiers in Endocrinology12649863. (https:\/\/doi.org\/10.3389\/fendo.2021.649863)"},{"key":"bib38","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"2916","article-title":"Clinical characters and influence factors of immune checkpoint inhibitor-related thyroid dysfunction","volume":"108","author":"Zhang","year":"2023","unstructured":"Zhang QJiao X & Lai X2023Clinical characters and influence factors of immune checkpoint inhibitor-related thyroid dysfunction. Journal of Clinical Endocrinology and Metabolism1082916\u20132923. (https:\/\/doi.org\/10.1210\/clinem\/dgad260)"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/31\/11\/ERC-24-0101.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/31\/11\/ERC-24-0101.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/31\/11\/ERC-24-0101.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:56:48Z","timestamp":1784555808000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/25814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":37,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.1530\/erc-24-0101","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]}}}